vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Laird Superfood, Inc. (LSF). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $13.3M, roughly 1.4× Laird Superfood, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -13.2%, a 12.4% gap on every dollar of revenue. On growth, Laird Superfood, Inc. posted the faster year-over-year revenue change (15.0% vs -25.7%). Over the past eight quarters, Laird Superfood, Inc.'s revenue compounded faster (16.1% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Laird Superfood, Inc. develops, manufactures and sells a portfolio of plant-based functional superfood products, including premium coffee creamers, hydration blends, nutritional supplements, and plant-powered snacks. It serves health-conscious consumers through direct-to-consumer e-commerce platforms and offline retail partners, mainly operating in the North American market with a focus on sustainably sourced clean ingredients.
CTMX vs LSF — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $13.3M |
| Net Profit | $-154.0K | $-1.8M |
| Gross Margin | — | 34.1% |
| Operating Margin | -6.9% | -13.5% |
| Net Margin | -0.8% | -13.2% |
| Revenue YoY | -25.7% | 15.0% |
| Net Profit YoY | 97.6% | -341.4% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $13.3M | ||
| Q3 25 | — | $12.9M | ||
| Q2 25 | $18.7M | $12.0M | ||
| Q1 25 | $50.9M | $11.7M | ||
| Q4 24 | $38.1M | $11.6M | ||
| Q3 24 | $33.4M | $11.8M | ||
| Q2 24 | $25.1M | $10.0M | ||
| Q1 24 | $41.5M | $9.9M |
| Q4 25 | — | $-1.8M | ||
| Q3 25 | — | $-975.1K | ||
| Q2 25 | $-154.0K | $-362.2K | ||
| Q1 25 | $23.5M | $-156.2K | ||
| Q4 24 | $18.9M | $-398.4K | ||
| Q3 24 | $5.7M | $-166.1K | ||
| Q2 24 | $-6.5M | $-239.1K | ||
| Q1 24 | $13.8M | $-1.0M |
| Q4 25 | — | 34.1% | ||
| Q3 25 | — | 36.5% | ||
| Q2 25 | — | 39.9% | ||
| Q1 25 | — | 41.9% | ||
| Q4 24 | — | 38.6% | ||
| Q3 24 | — | 43.0% | ||
| Q2 24 | — | 41.8% | ||
| Q1 24 | — | 40.0% |
| Q4 25 | — | -13.5% | ||
| Q3 25 | — | -7.7% | ||
| Q2 25 | -6.9% | -3.3% | ||
| Q1 25 | 44.4% | -1.9% | ||
| Q4 24 | 46.4% | -4.1% | ||
| Q3 24 | 12.3% | -2.3% | ||
| Q2 24 | -33.7% | -3.4% | ||
| Q1 24 | 28.1% | -11.0% |
| Q4 25 | — | -13.2% | ||
| Q3 25 | — | -7.6% | ||
| Q2 25 | -0.8% | -3.0% | ||
| Q1 25 | 46.2% | -1.3% | ||
| Q4 24 | 49.6% | -3.4% | ||
| Q3 24 | 17.2% | -1.4% | ||
| Q2 24 | -26.0% | -2.4% | ||
| Q1 24 | 33.3% | -10.3% |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $5.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $11.5M |
| Total Assets | $175.1M | $19.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $5.1M | ||
| Q3 25 | — | $5.1M | ||
| Q2 25 | $49.0M | $3.9M | ||
| Q1 25 | $47.6M | $7.0M | ||
| Q4 24 | $38.1M | $8.3M | ||
| Q3 24 | $40.6M | $7.9M | ||
| Q2 24 | $43.2M | $7.6M | ||
| Q1 24 | $36.2M | $7.1M |
| Q4 25 | — | $11.5M | ||
| Q3 25 | — | $12.8M | ||
| Q2 25 | $119.9M | $13.4M | ||
| Q1 25 | $25.0M | $13.3M | ||
| Q4 24 | $-456.0K | $13.2M | ||
| Q3 24 | $-23.5M | $13.1M | ||
| Q2 24 | $-31.2M | $12.6M | ||
| Q1 24 | $-31.7M | $12.7M |
| Q4 25 | — | $19.2M | ||
| Q3 25 | — | $18.9M | ||
| Q2 25 | $175.1M | $20.4M | ||
| Q1 25 | $98.5M | $21.5M | ||
| Q4 24 | $120.5M | $19.3M | ||
| Q3 24 | $139.0M | $18.8M | ||
| Q2 24 | $159.2M | $18.0M | ||
| Q1 24 | $184.7M | $17.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $68.4K |
| Free Cash FlowOCF − Capex | $-15.8M | — |
| FCF MarginFCF / Revenue | -84.6% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $68.4K | ||
| Q3 25 | — | $1.2M | ||
| Q2 25 | $-15.8M | $-2.8M | ||
| Q1 25 | $-21.0M | $-1.3M | ||
| Q4 24 | $-19.9M | $339.2K | ||
| Q3 24 | $-20.7M | $305.8K | ||
| Q2 24 | $-19.5M | $642.7K | ||
| Q1 24 | $-26.0M | $-422.3K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.2M | — | ||
| Q4 24 | $-20.0M | — | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.6M | — | ||
| Q1 24 | $-26.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -84.6% | — | ||
| Q1 25 | -41.6% | — | ||
| Q4 24 | -52.5% | — | ||
| Q3 24 | -62.1% | — | ||
| Q2 24 | -78.2% | — | ||
| Q1 24 | -63.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
LSF
| Wholesale | $7.0M | 52% |
| Coffee Tea And Hot Chocolate Products | $4.4M | 33% |
| Hydration And Beverage Enhancing Supplements | $1.6M | 12% |
| Other | $352.6K | 3% |
